A pelvic mass is one of the most frequent indications for re fe rral to specialist gynecologists. Often, these pelvic masses are malignant and require surgical treatment. Up to 24% of ova rian tumors in premenopausal women are malignant and up to 60% are malignant in postmenopausal women [13] . The preoperative diagnosis of whether a mass is malignant cannot always be made with current diagnostic modalities. Surgery can be optimally planned if an ovarian neoplasm is known to be benign or malignant in advance. The type of surgical procedure and the experience of the surgeon are im portant factors for the prognosis of ovarian cancer. An impro ved method for preoperative discrimination of a pelvic mass would result in more women receiving firstline therapy from appropriately trained and experienced personnel [4, 5] . For such referrals to be efficient, improved specific and sensitive methods for diagnosing ovarian cancers are needed. 
INTRODUCTION
178 www.ejgo.org of CA125. This has given much better results than a single parameter [1823] . The RMI can be applied in less specialized centers. The risk of malignancy index is the product of the ultrasound scores (U), the menopausal score (M), and the ab solute value of serum CA125 levels: RMI = U x M x CA125.
In the 1990s, Jacobs et al. [18] originally developed the RMI, which is now termed RMI 1. Tingulstad et al. [19] developed their version of the RMI in 1996 and it is known as RMI 2. In 1999, Tingulstad et al. [20] modified the RMI, which is termed RMI 3. Yamamoto et al. [24] created their own model of a ma lignancy risk index. They added the parameter of the tumor size (S) to the RMI and have termed it the RMI 4.
The purpose of this study was to evaluate the ability of the four malignancy risk indices to discriminate a benign from a malignant pelvic mass and to evaluate the performances of the four malignancy risk indices.
MATERIALS AND METHODS
The clinical data of 100 women with pelvic masses ap pointed for laparotomy or laparoscopy between October 1, 2008, and February 3, 2010, to our hospital were obtained. We began our trial to compare RMI 1, RMI 2, and RMI 3 with each other. During the data collection period, in 2009, Yamomoto et al. [24] published their study about RMI 4. So we calculated RMI 4 scores of masses retrospectively before 2009 and pro spectively after that year. Preoperative serum CA125 levels, ultrasound findings, and menopausal status were noted. The ultrasound was performed transvaginally by a 7.5MHz trans ducer (Siemens, Antares Sonoline, CA, USA). A transabdominal repeat examination with a full bladder was obtained if a mass was found to be too large to be observed completely trans vaginally. A score was assigned for the following ultrasound features suggestive of malignancy: the presence of a multi locular cystic lesion, solid areas, bilateral lesions, ascites, and intraabdominal metastases, scored as one point for each. A total ultrasound score (U) was thus calculated for each patient. Tumor size (S) was measured by ultrasound for each patient. Postmenopausal status was defined as more than 1 year of amenorrhea or age older than 50 years in women who had undergone hysterectomy. All other women were considered premenopausal. Serum samples were collected preoperatively and serum CA125 levels were measured using Electrochemi luminescence Immunoassaay (ECLIA) (Roche Elecsys E 1701) in accordance with the manufacturer's instructions. Based on the data obtained, RMI 1, RMI 2, RMI 3, and RMI 4 were calcu lated for all patients together with the sensitivity, specificity, diagnostic accuracy and positive and negative predictive val ues of the four methods as follows:
1. RMI 1 (Jacobs et al. 1990 A tumor size (single greatest diameter) of <7 cm made S=1, and ≥7 cm made S=2. The serum level of CA125 was applied directly to the calculation [24] . The histopathological diagnosis was considered as the gold standard for definite outcome. We did not include borderline tumors in our study. When a gynecological cancer was found, it was staged according to the International Federation of Gynecology and Obstetrics classification [21] . All statistical analyses were performed using the SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA). The x² test was used to test differences in distribution of age, menopausal status, and ultrasound score. The MannWhitney Utest was applied when testing differ ences in distribution of CA125 among women with benign and malignant pelvic masses. The McNemar's test was used when testing differences in performances between RMI 1, RMI 2, RMI 3, and RMI 4. The sensitivity was defined as the percent age of patients with malignant disease having a positive test result. The specificity was defined as the percentage with benign disease having a negative test result. The positive pre dictive value was defined as the percentage of patients with a positive test result having malignant disease and the negative predictive value was defined as the percentage of patients with a negative test result having benign disease.
RESULTS
As a result of the histological examination of the surgical spe ci mens of 100 patients, 80 (80%) had benign and 20 (20%) www.ejgo.org 179 had malignant disease ( Table 1) . The histopathological clas sification of all cases and the stage distribution of malignant ones are given in Table 1 . The distribution of benign and malignant cases by age, menopausal status, tumor size and ultrasound score is described in Table 2 . In univariate analysis a significant linear trend for malignancy was found by increas ing ultrasound score and the occurrence of malignancy in the pre and postmenopausal patients. Although the risk of ma lignancy was increasing by age, it did not reach the statistical significance (p=0.051).
The mean serum level of CA125 was significantly higher among women with malignancy when compared with women with benign tumors (329.2310 U/mL vs. 28.0374 U/ mL). The sensitivity, specificity, and positive and negative pre dictive values and diagnostic accuracy of serum CA125 level of 35 U/mL, the ultrasound score of 2, postmenopausal status and the size of 7 centimeters are reported in Table 3 . When individual parameters were compared in Table 3 , CA125 had better sensitivity than the ultrasound score, size and meno pausal status, even though the others had higher specificity We think that risk of malignancy indices were more reliable in detecting malignancy in terms of area under the curves. The diagnostic performance of ultrasound score, CA125, menopausal sta tus, tumor size, RMI 1, RMI 2, RMI 3, and RMI 4 is shown in the receiveroperating characteristic curves (Fig. 1) .
DISCUSSION
This study has revealed the usefulness of RMI to correctly dis criminate benign from malignant pelvic masses. The RMI was Table 4 . Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values, and diagnostic accuracy (DA) for detecting malignancy at different cutoff levels of RMI 1, RMI 2, RMI 3, and RMI 4 www.ejgo.org 181 originally developed by Jacobs et al. [18] , and subsequently the same group reproduced the results in a second patient group, establishing the superiority of RMI over the individual parameters [22] . In our patient group we found that there is no statistically significant difference in the performance of these four differ ent malignancy risk indices (RMI 1, RMI 2, RMI 3, and RMI 4) in discriminating malignancy. But RMI 2 was found to be more reliable in discriminating benign and malignant disease by other investigators [19, 23] . Tingulstad et al. [19] developed their RMI in 1996 and called it RMI 2. They compared it with that established by Jacobs et al. [18] and found that at a cutoff level of 200, a direct comparison of the two indices showed that RMI 2 was significantly better than RMI 1 (McNemar test, p=0.001). Morgante et al. [23] also found a similar result that for all cutoff values between 80 and 250, RMI 2 performed better than RMI 1 (p=0.0001). Tingulstad et al. [20] modified the RMI and defined it RMI 3, and they observed that at a cut off level of 200 the sensitivity and specificity were 71 and 92%, respectively.
In 2001 Manjunath et al. [25] compared RMI 1, RMI 2, and RMI 3 with each other and also confirmed that there was no statistical difference between these three indices in benign malignancy discrimination. In their study, Clarke et al. [26] , using a cutoff of 120, found that RMI 1 had a sensitivity of 72% and a specificity of 87%; RMI 2 had a sensitivity of 76% and a specificity of 81%; RMI 3 had a sensitivity of 74% and a specificity of 84%. In 2009 Yamamoto et al. [24] developed their own RMI by using tumor size and called it RMI 4. Their study confirms that, at a cutoff level of 450, the accuracy of the RMI 4 was better than RMI 1 (p=0.0013), RMI 2 (p=0.0009) and RMI 3 (p=0.0013) with a cutoff level of 200. They observed that at a cutoff level of 450 the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were respectively, 86.8%, 91.0%, 63.5%, 97.5%, and 90.4% [24] . In our study we found a sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 85%, 87%, 60%, 95%, and 86%, respectively, which is comparable with the results of Yamamoto et al. [24] . But we also found that the other three indices' diagnostic performances were reliable, being different than Yamomoto et al's results.
The risk of malignancy index is a simple scoring system, ap pears to be very accurate, is useful in clinical practice, and should therefore be the test of choice in the preoperative evaluation of the adnexal mass. Any of the four malignancy risk indices (RMI 1, RMI 2, RMI 3, RMI 4) described can be used for selection of cases for optimal therapy. Since the specific ity of risk of malignancy index is high, there is a potential role for this index in the selection of cases for conservative man agement or minimal invasive surgery of benign cases, like ultrasound guided aspiration or laparoscopic excision of other cysts.
